Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
105 hedge funds and large institutions have $305M invested in Carisma Therapeutics in 2021 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 31 increasing their positions, 21 reducing their positions, and 13 closing their positions.
223% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 13
193% more capital invested
Capital invested by funds: $104M → $305M (+$201M)
48% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 21
38% more funds holding
Funds holding: 76 → 105 (+29)
36% more call options, than puts
Call options by funds: $6.74M | Put options by funds: $4.96M
0.73% more ownership
Funds ownership: 1.18% → 1.91% (+0.73%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$43.2M |
| 2 |
BlackRock
New York
|
+$24.7M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.93M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$4.42M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$7.91M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$3.41M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.18M |
| 4 |
HF
HRT Financial
New York
|
-$986K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$921K |
CARM Hedge Fund Activity: Q2 2021 in Review
105 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2021, worth a combined $305M — up 193% from $104M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new CARM positions and 13 closed out — a net gain of 29 holders — while 31 added to existing stakes and 21 trimmed.
The largest buyer was State Street, adding an estimated $43.2M. The largest seller was Renaissance Technologies, cutting an estimated $7.91M.
- 105 institutional investors held Carisma Therapeutics (CARM) as of Q2 2021, up from 76 in Q1 2021.
- Funds reported $305M of Carisma Therapeutics stock for Q2 2021, up 193% quarter-over-quarter.
- 42 funds opened new Carisma Therapeutics positions in Q2 2021 and 13 closed out, a net change of +29 holders.
- The largest Carisma Therapeutics buyer in Q2 2021 was State Street, an estimated $43.2M added.
- The largest Carisma Therapeutics seller in Q2 2021 was Renaissance Technologies, an estimated $7.91M sold.
Based on aggregated 13F filings for Q2 2021.